Meeting
2024 ASCO Annual Meeting
CODOX-M/IVAC-R versus DA-EPOCH-R in double/triple-hit large B cell lymphoma in patients ≤ 60 years.
Authors
Suheil Albert Atallah-Yunes
Division of Hematology, Mayo Clinic, Rochester, MN
Suheil Albert Atallah-Yunes , Matthew J. Rees , Thomas E. Witzig , Thomas Matthew Habermann , Ellen D McPhail , Javier Munoz , Madiha Iqbal , Grzegorz S. Nowakowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7067)
DOI
10.1200/JCO.2024.42.16_suppl.7067
Abstract #
7067
Poster Bd #
50
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).
First Author: Ruemu Ejedafeta Birhiray
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi
Poster
2022 ASCO Annual Meeting
Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial.
First Author: Musa Yilmaz